CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries
CG01 has previously been granted patents in the USA and Russia. CG01 is a unique gene therapy candidate aimed at a large patient population to solve an unmet need in epilepsy treatment. Epilepsy is a major global medical problem with approximately 47,000 drug-resistant patients with focal epilepsy estimated to be added each year in the US, EU4, UK, Japan, and China. CG01 is in preclinical stage.